Dantrolene-13C3
CAT:
804-HY-12542S-01
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Dantrolene-13C3
- Alternative Name: F 368-13C3
- CAS Number: 1185234-99-4
- UNSPSC Description: Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
- Target Antigen: Glutathione Reductase; Isotope-Labeled Compounds
- Type: Isotope-Labeled Compounds
- Related Pathways: Metabolic Enzyme/Protease;Others
- Field of Research: Inflammation/Immunology; Neurological Disease
- Assay Protocol: https://www.medchemexpress.com/dantrolene-13c3.html
- Purity: 99.0
- Solubility: 10 mM in DMSO
- Smiles: O=[13C](N[13C]1=O)[13CH2]N1/N=C/C2=CC=C(C3=CC=C(C=C3)[N+]([O-])=O)O2
- Molecular Weight: 317.23
- References & Citations: [1]F Zhao, et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem. 2001 Apr 27;276(17):13810-6.|[2]Murat Sentürk, et al. Dantrolene inhibits human erythrocyte glutathione reductase. Biol Pharm Bull. 2008 Nov;31(11):2036-9.|[3]Shigeki Kobayashi, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol. 2009 May 26;53(21):1993-2005.|[4]W J Meyler, et al. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. Eur J Pharmacol. 1979 Feb 1;53(4):335-42.|[5]Xi Chen, et al. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener. 2011 Nov 25;6:81.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: No Development Reported